Get the Stockscreener App
98.47
0.41%
0.4821
Revolution Medicines Inc stock is traded at $98.47, with a volume of 836.50K.
It is up +0.41% in the last 24 hours and down -16.03% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$97.99
Open:
$98.65
24h Volume:
836.50K
Relative Volume:
0.26
Market Cap:
$19.00B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-26.90
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+2.33%
1M Performance:
-16.03%
6M Performance:
+179.04%
1Y Performance:
+134.26%
1-Day Range:
$97.20
$98.79
1-Week Range:
$93.79
$99.58
52-Week Range:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
98.27 | 18.94B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.48 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.58 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.23 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.77 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.52 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines, Inc. $RVMD Shares Sold by Allianz Asset Management GmbH - MarketBeat
Revolution Medicines at Guggenheim Biotech Summit: Strategic Focus on RAS Inhibitors - Investing.com Canada
How Revolution Medicines Inc. stock reacts to Fed rate cutsJuly 2025 Macro Moves & Real-Time Volume Analysis - mfd.ru
Stock Traders Purchase High Volume of Put Options on Revolution Medicines (NASDAQ:RVMD) - MarketBeat
Can Revolution Medicines Inc. Equity Warrant stock reach $100 price targetJuly 2025 Action & Accurate Intraday Trade Tips - mfd.ru
Revolution Medicines, Inc. $RVMD Shares Bought by Candriam S.C.A. - MarketBeat
Layoff Watch: Is Revolution Medicines Inc Equity Warrant subject to activist investor interestMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Update Report: Will Revolution Medicines Inc outperform during market rallies - baoquankhu1.vn
Market Review: Is Revolution Medicines Inc a defensive stockExit Point & Fast Moving Stock Trade Plans - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Acquired by New York State Common Retirement Fund - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines jumps on report AbbVie nears takeover - MSN
Earnings Recap: Is Revolution Medicines Inc affected by consumer sentimentJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
(RVMD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - The Manila Times
Revolution Medicines (RVMD) Price Target Increased by 24.66% to 115.71 - Nasdaq
Revolution Medicines (BIT:1RVMD) Price Target Increased by 30.97% to 100.64 - Nasdaq
Bearish Sentiment Observed in Revolution Medicines (RVMD) - GuruFocus
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine - PharmTech.com
Revolution Medicines plummets on report Merck walks from acquisition talks - MSN
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate - FinancialContent
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $122.00 - MarketBeat
Revolution Medicines (RVMD) Gets Price Target Boost from JP Morg - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Evaluating the 19.27% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Knights of Columbus Asset Advisors LLC Takes $587,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Why Revolution Medicines stock plummeted by almost 17% today - MSN
Revolution Medicines stock stares at big dip after Merck reportedly shelves buyout — but analyst flags opportunity - MSN
Merck is said to halt acquisition talks with cancer drug developer Revolution - MSN
Market Outlook: Is now the right time to enter Revolution Medicines IncWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Merck Ends Revolution Talks As Oncology Focus And Valuation Take Center Stage - Sahm
RVMD stock tumbles as MRK reportedly withdraws buyout offer - MSN
Revolution Medicines shares slide after Merck reportedly walks away from takeover talks - MSN
What is Revolution Medicines Inc.’s market positionWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Revolution Medicines (RVMD) Initiates First Human Trial for RMC-5127 - GuruFocus
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor - GlobeNewswire
48,000 RAS G12V cancer cases a year as Revolution Medicines trials new drug - Stock Titan
Y Intercept Hong Kong Ltd Has $2.58 Million Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed - Yahoo Finance
Oppenheimer Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer - Yahoo Finance
Truist Financial Initiates Revolution Medicines(RVMD.US) With Buy Rating - 富途牛牛
Oppenheimer Raises Price Target for Revolution Medicines (RVMD) - GuruFocus
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan - Insider Monkey
10 Big Names Stumbling Hard - Insider Monkey
Revolution Medicines Shares Plunge 17% After Merck Acquisition Talks Stall - Intellectia AI
Why Revolution Medicines Stock Plummeted by Almost 17% Today - Finviz
Why Revolution Medicines Stock Plummeted by Almost 17% Today - The Motley Fool
Revolution’s shares dip with report of Merck walking away: Deals Report - biocentury.com
Merck stock slips after report says MRK stepped back from Revolution Medicines talks - TechStock²
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
2.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):